Objective:
The article examines the objective, findings, and clinical context described in Argentina Streamlines Clinical Trial Approval Procedures.
Approach:
- Activity: Cardozo presented ANMAT approval figures and data on research centers and ophthalmology studies.
- Regulatory framework: He reviewed ANMAT Disposition 7516/2025, effective December 1, 2025, which adopted ICH E6(R3) Good Clinical Practice guidelines for specified phase 1–3 drug studies intended to support registration.
- Review process: The revised process allows regulatory and ethics committee submissions to proceed in parallel. ANMAT reviews study protocols; ethics committees assess informed consent and other participant-facing materials.
Key Findings:
- ANMAT approved 291 clinical pharmacology studies from January through September 2026, 36% more than in the same period of 2025 and more than the 290 approved during all of 2025.
- Thirteen ophthalmology studies were submitted from January through October 2026, compared with 6 in 2025 and 7 in 2024.
- Of 1,287 research centers nationwide, 297 were identified as actively conducting research; more than half of all centers were concentrated in Buenos Aires city and province.
- Thirty-two ophthalmology research centers were identified across 9 provinces; more than 65% were in Buenos Aires city or province.
- CEIG generally provides initial responses and reviews sponsor replies within 2 to 5 business days; this timeframe does not necessarily indicate time to final approval.
Interpretation:
Cardozo said the revised procedures may streamline submissions, while differing provincial requirements and the concentration of research centers remain challenges to broader participation.
Limitations:
- The article reports figures and observations presented at the SARyV meeting; it does not provide independent verification or detailed methods for the center counts.
- The 2-to-5-business-day CEIG timeframe refers to initial responses and sponsor-reply reviews, not necessarily final approval.
Conclusion:
Cardozo also called for expanding research beyond major urban centers and providing continuing training for investigators and research teams.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.